PHVS Pharvaris NV

Pharvaris Announces Annual Meeting of Shareholders

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at . Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit .

Investor Contact

Sarah McCabe

Stern Investor Relations, Inc.



Media Contact

Maggie Beller

Russo Partners, LLC





EN
11/06/2021

Underlying

PHVSPharvaris NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharvaris NV

 PRESS RELEASE
Free
PHVS PHARVARIS NV

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and O...

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioede...

March 20, 2026 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Validation of Patient-Reported Outcomes in the On-Demand Treatment of ...

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykin...

March 11, 2026 1 EN
Jacob Mekhael ... (+4)
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Wim Hoste
ACKB ACKERMANS & VAN HAAREN NV
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
PHVS PHARVARIS NV
SYENS SYENSQO
03/03/26 March 3, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
PHVS PHARVARIS NV

Pharvaris Presents supportive data for deucrictibant in HAE at AAAAI

Pharvaris presented multiple datasets for deucrictibant in HAE patients in both the on-demand and prophylactic settings at the AAAAI conference. While acknowledging the usual caveats of cross-trial comparison, we believe the data gives deucrictibant a slight edge over Ekterly in the on-demand setting, where a larger proportion of deucrictibant-treated patients achieved onset of symptom relief within 12 hours (90% vs. 76% with Ekterly). In the phase 2 OLE in the prophylactic setting, long term ou...

03/03/26 March 3, 2026 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Deucrictibant Data Supporting Potentially Differentiated Profile for t...

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacksFinal CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant for the prevention of HAE attack...

March 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch